Navigation Links
AXIOM Artis FA

ProductsAXIOM Artis FA
Company Siemens Medical Solutions USA, Inc.
Item AXIOM Artis FA
Features 
  • Connectivity: Intended to help eliminate communication problems
  • Image Quality: More than just good images, brilliant results
  • Care: Nothing else on the market compares with our new standards in radiation protection, offering superior image quality
  • Ease of Use: User friendly the new concept of intuitive operation
Description AXIOM Artis FA is a universal floor-mounted angiographic C-arm system whose flexible system architecture is ideal for vascular and non-vascular diagnostics and interventions. It provides complete ergonomic system operation in both the examination room and control room.
Info Siemens Medical Solutions USA, Inc.
Customer Service: (888) 826-9702
Web site: http://www.usa.siemens.com/medical

Related medicine products :

1. AXIOM Multistar
2. AXIOM Artis TA
3. AXIOM CT Miyabi
4. AXIOM Artis dBC
5. AXIOM Artis dFC
6. AXIOM Artis BC
7. AXIOM Artis FC
8. AXIOM Artis TC
9. AXIOM Artis U
10. AXIOM Artis dTC
11. AXIOM Artis dFC Magnetic Navigation
TAG: AXIOM Artis
...y™ Elbow and Hand Spasticity Orthosis decrea...tremity post-stroke. Treat elbow, forearm, wrist s... patient and adjust to meet available passive ROM....mponent. Then apply hand cone to the bar. Use incl...
...Elbow Cryo/Cuff combines the therapeutic benefits ... and swelling, and cold to minimize pain. The cuff...bow providing maximum cryotherapy. The Elbow Cryo/...a pediatric size.,All Cryo/Cuffs can be ordered as...
...FoamWrap ACTION Elbow Wrap replaces messy taping a... and others experiencing epicondylitis. Preferred ...d non-bulky fit. Two overlay straps allow you to a... lining holds the Elbow Wrap comfortably in place....
...contour design of this lightweight brace allows it...lizes the ankle joint following severe sprains, te...piral stays move with the ankle and provide optimu... splint control rotational strains on the ankle, a...
Medicine Products:
(Date:7/25/2008)...ormer McKesson Corporation Executive, Robert J. Re...ewswire/ -- Aethon Inc.,( http://www.aethon.com ),...ital supply chain logistics, today announced that ...Vice President -- Chief Financial Officer., Reill... Manager for,McKesson Corporation,s Specialty Phar...
(Date:7/25/2008)... HOUSTON, July 25 /PRNewswire/ -- The Elekta Fami... cancer treatment solutions at the 2008,American A... meeting,demonstrating how the joint forces of El...diation therapy planning and delivery solutions th...tter experience for,patients, as well as enhance c...
(Date:7/25/2008)... CARLSBAD, Calif., July 25 /PRNewswire/ -- AutoGe...egistration statement on Form S-1 with the,Securit...ed initial public,offering of shares of its common... offered, all of which are expected to be offered ... offering, have not yet been,determined., J.P. Mo...
(Date:7/25/2008)...turday can be toughest for those trying to drop po...ealthDay News) -- Anyone who has avoided Monday mo...ends are not a dieter,s friend. , Now, research...ts about weekends being their undoing: Most people...ing to lose weight. , "Weekend indulgences can ...
Breaking Medicine News(10 mins):Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3
...he biggest killer disease in the UK during the 180...rom 2004 to 2005. //Th number of cases have been r...single largest leap , causing great concern to go...which killed several famous poets like John Keats ...
...y stages of life may grow up to become an abusive ... of Chicago. //This study was conducted on baby rh...e may lead to the production of less seratonin, a ...brain. Low levels of serotonin causes anxiety and ...
...ers will have it tough, to fight reality staring a...the potential //damage smoking can cause! This mo...o ahead for the use of images on cigarette packets...ctures of diseased lungs, decaying teeth, gangreno...
...velation pointed out that although very difficult ...d roughly // that about 10%- 25% of the funds allo...lic by the governments globally gets misused or lo...iversion of pharmaceuticals. In a rough estimate i...
Other Medicine News:Health News:TB Returns , Sharp Rise In Cases In UK 2Health News:An abused child may grow up to be an abusive parent 2Health News:An abused child may grow up to be an abusive parent 3
(Date:7/23/2008)...- Sound Pharmaceuticals (SPI) has filed,an Investi... clinical,testing of a proprietary formulation of ... hearing loss or ototoxicity. The oral capsule,con...ced stage lung cancer,and head and neck cancer pat...marks the second development program for SPI to en...
(Date:7/23/2008)...rstCall/ -- Dendreon Corporation,(Nasdaq: DNDN ) ...ta,Monitoring Committee (IDMC) to review in Octobe...lating to the Company,s Phase 3 IMPACT (IMmunother...own as D9902B) clinical trial,of PROVENGE(R) (sipu...al,active cellular immunotherapy for the treatment...
(Date:7/22/2008)...s Development Initiative bring MJFF,s,current acti...nuary 20,2009, NEW YORK, July 22 /PRNewswire-USN...ry of transformative treatments and a cure for Par...r Parkinson,s Research has awarded,$2.7 million in... awards,were granted under MJFF,s Therapeutics Dev...
(Date:7/22/2008)...he Importance to Patients of Passing a ...OND, Va., July 22 /- Insmed...iologics and biopharmaceuticals, today,announced t...sent at a,Congressional briefing on Friday, July 2...blishing an approval pathway for follow-on,biologi...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Transdel Initiates Ketotransdel 28TM 29 Phase 3 Clinical Program for Pain 2434 1Transdel Initiates Ketotransdel 28TM 29 Phase 3 Clinical Program for Pain 2434 2Transdel Initiates Ketotransdel 28TM 29 Phase 3 Clinical Program for Pain 2434 3Transdel Initiates Ketotransdel 28TM 29 Phase 3 Clinical Program for Pain 2434 4Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin 28formerly SNS 595 29 in Patients with Acute Myeloid Leukemia at the 13th Con 2431 1Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin 28formerly SNS 595 29 in Patients with Acute Myeloid Leukemia at the 13th Con 2431 2Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin 28formerly SNS 595 29 in Patients with Acute Myeloid Leukemia at the 13th Con 2431 3Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin 28formerly SNS 595 29 in Patients with Acute Myeloid Leukemia at the 13th Con 2431 4Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin 28formerly SNS 595 29 in Patients with Acute Myeloid Leukemia at the 13th Con 2431 5Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin 28formerly SNS 595 29 in Patients with Acute Myeloid Leukemia at the 13th Con 2431 6Cardiva Medical Inc to Present at the Investment In Innovation 28In3 29 Medical Device Summit on June 18 2008 in San Francisco CA 3B Announces th 21891 1Cardiva Medical Inc to Present at the Investment In Innovation 28In3 29 Medical Device Summit on June 18 2008 in San Francisco CA 3B Announces th 21891 2PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5997 1PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5997 2PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5997 3PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5997 4PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5997 5PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5997 6PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5997 7
...NA, Calif.--(BUSINESS WIRE)--Jun 1, 2007 - Arrowhe...day that interim Phase I data,has been published i...Proceedings (ASCO) (Abstract ID 32638). The data a... to evaluate the safety,tolerability, and pharmac...IT-101, in patients with inoperable or metastatic,...
... SAN FRANCISCO, Calif., June 01, 2007,/PRNewswire-...announced that the company will present data from ... the 12th Congress of the European,Hematology Asso...,Austria. , Presentations will include updated in...al of SNS-595 in acute leukemias, as,well as clini...
Other Medicine Technology:Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug 2Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug 3Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3